Risk of first-time major cardiovascular event among individuals with newly diagnosed type 2 diabetes: data from Danish registers.

ABSTRACT:

Aims/hypothesis

We aimed to examine whether individuals with initial omission of glucose-lowering drug treatment (GLDT), including those achieving initial remission of type 2 diabetes, may experience a higher risk of major adverse cardiovascular events (MACE) compared with well-controlled individuals on GLDT after a new type 2 diabetes diagnosis in real-world clinical practice. Furthermore, we examined whether a higher risk could be related to lower initiation of statins and renin-angiotensin system inhibitors (RASi).

Methods

In this cohort study, we used Danish registers to identify individuals with a first measured HbA_1c between 48 and 57 mmol/mol (6.5-7.4%) from 2014 to 2020. Six months later, we divided participants into four groups according to GLDT and achie

SUBMITTER: Falkentoft AC 

PROVIDER: S-EPMC10541344 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature